查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1896150

数位疗法市场预测至2032年：按疗法类型、部署方式、技术、应用、最终用户和地区分類的全球分析

Digital Therapeutics Market Forecasts to 2032 - Global Analysis By Treatment Type, Deployment, Technology, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的一项研究，预计到 2025 年，全球数位疗法市场规模将达到 66 亿美元，到 2032 年将达到 295 亿美元，预测期内复合年增长率为 23.8%。

数位疗法是基于循证医学的软体应用程序，旨在透过临床检验的数位干预措施来预防、管理和治疗疾病。它们利用行为科学、认知疗法、即时监测和个人化护理管道，从而显着改善患者的治疗效果。数位疗法可以补充或取代传统治疗方法，尤其是在慢性病管理、精神健康、代谢失调和神经系统疾病方面。数位疗法在监管下运行，并与医疗系统连接，以实现数据驱动的连续性护理和远距临床支援。

根据 IQVIA 的数位健康趋势更新报告，每月使用处方笺级数位疗法的患者人数已超过 3.7 亿，高于 2020 年的 1.1 亿，这表明慢性病管理中已广泛采用数位疗法。

远端患者管理的日益普及

随着医疗生态系统向虚拟医疗模式转型，远距病患管理的日益普及正在加速对数位疗法的需求。慢性病盛行率的上升和远端医疗平台接受度的提高进一步推动了这一趋势。能够实现即时监测、药物依从性追踪和行为健康介入的数位工具已被证实具有可衡量的临床益处。医疗服务提供者正在寻求可扩展且经济高效的方式来管理大规模的患者群体，而数位疗法在支持持续参与、提高治疗依从性和改善长期健康结果方面正变得至关重要。

许多地区的报销范围有限

许多地区有限的报销覆盖范围仍然是大规模推广应用的一大障碍，尤其是在软体治疗方法监管管道不完善的地区。支付方往往不愿意将数位疗法纳入可报销范围，减缓了其融入主流医疗保健体系的进程。评估标准不统一以及临床经济学证据不足进一步加剧了资金筹措决策的复杂性。因此，医疗服务提供者和患者经常需要自付费用，阻碍了数位疗法的广泛应用。在全球报销框架成熟之前，不同医疗保健体系的市场渗透率可能仍将不平衡。

与个人化照护管道的整合

随着数位疗法越来越多地利用人工智慧驱动的洞察、行为分析和患者特异性生物标誌物，与个人化医疗管道的整合具有巨大的发展潜力。在慢性病、代谢性疾病和精神疾病领域，个人化治疗方案能够提高疗效、增强病人参与并降低復发率。日益丰富的真实世界数据强化了临床检验，并促进了实证医疗模式的应用。随着医疗保健向精准医疗发展，能够提供个人化治疗优化的数位平台正日益成为实现以患者为中心的干预措施的关键基础。

资料安全漏洞影响病患信任

由于数位疗法高度依赖敏感的行为、临床和生物识别数据，因此，损害患者信任的数据安全漏洞仍然是一个重大威胁。云端基础设施、行动应用程式和API整合中的网路漏洞可能导致个人健康资讯洩露，并削弱用户信任。不遵守监管规定可能导致处罚和医疗设备认证延迟。除非平台展现出强大的网路安全态势和透明的资料处理实践，否则大众对数位隐私日益严格的审查可能会减缓数位疗法的广泛应用。

新冠疫情的影响

新冠疫情显着加速了数位疗法的普及，因为在封锁期间，医疗系统优先考虑远距医疗模式。患者更多地使用基于应用程式的干预措施、数位认知行为疗法工具和慢性病追踪平台，以避免线下就诊。临床检查也转向线上形式，这提高了监管机构和医疗服务提供者的接受度。疫情提高了人们对可扩展数位医疗管道的认识，疫情后，随着混合医疗模式的持续发展，需求依然强劲，这巩固了数位疗法在治疗服务中的长期作用。

预计在预测期内，慢性病管理系统细分市场将占据最大的市场份额。

由于糖尿病、心血管疾病、呼吸系统疾病和文明病的盛行率不断上升，预计慢性病管理系统细分市场将在预测期内占据最大的市场份额。这些平台提供系统化的监测、行为指导和治疗强化，进而提升患者的自我管理能力。医疗服务提供者越来越依赖此类系统来减少住院次数、优化护理协调并提高治疗依从性。经证实的临床有效性和广泛的适用性确保了其在数位疗法领域的持续领先地位。

预计在预测期内，云端平台细分市场将实现最高的复合年增长率。

由于其可扩展性、互通性和跨医疗系统无缝资料整合能力，预计在预测期内，云端平台细分市场将实现最高的成长率。云端架构支援即时分析、远端存取和持续的病人参与，同时降低营运成本。它支援多设备同步，并有助于纵向监测和自动化治疗协调。随着对柔软性、安全且易于部署的数位健康解决方案的需求不断增长，云端平台正迅速崛起为成长最快的细分市场。

比最大的地区

预计亚太地区将在整个预测期内保持最大的市场份额，这主要得益于不断扩展的数位医疗计划、智慧型手机的快速普及以及慢性病负担的日益加重。中国、印度、日本和韩国等国的政府正在加速推广远端医疗计画和基于应用程式的治疗工具。医疗保健的日益数位化、有利于远端医疗的法规环境以及庞大的患者群体进一步推动了这些技术的普及。所有这些因素巩固了亚太地区作为数位疗法应用领先市场的地位。

最高复合年增长率地区

在预测期内，由于医保报销机制的不断改进、数位疗法快速融入临床工作流程以及强劲的创业投资资金筹措，北美地区预计将实现最高的复合年增长率。领先的数位医疗创新者、支持性的法规结构以及医疗服务提供者与科技公司之间日益紧密的伙伴关係，正在加速数位疗法的普及应用。对以结果为导向的医疗保健的日益重视以及远距远端医疗干预措施的广泛接受，进一步巩固了北美作为成长最快区域市场的地位。

免费客製化服务

购买此报告的客户可享有以下免费自订选项之一：

  • 公司概况
    • 最多三家新增市场参与企业进行全面分析
    • 主要参与企业（最多3家公司）的SWOT分析
  • 区域细分
    • 根据客户要求，提供主要国家的市场规模、估算、预测和复合年增长率（註：可行性需确认）。
  • 竞争基准化分析
    • 从产品系列、地域覆盖范围和策略联盟等方面对主要参与企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 摘要
  • 相关利益者
  • 调查范围
  • 调查方法
  • 研究材料

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球数位疗法市场（依治疗类型划分）

  • 行为健康计划
  • 慢性病管理系统
  • 实体復健平台
  • 生活方式和营养干预
  • 神经系统治疗方案
  • 药物滥用/成瘾治疗

6. 全球数位疗法市场（以部署方式划分）

  • 基于云端的平台
  • 本地部署平台
  • 混合数位治疗系统
  • 订阅式平台
  • 综合医院平台

7. 全球数位疗法市场（按技术划分）

  • 基于人工智慧的治疗平台
  • 行动和应用程式解决方案
  • 穿戴式整合系统
  • 远端监控技术
  • VR/AR治疗平台
  • 数据分析云端系统

第八章 全球数位疗法市场（按应用领域划分）

  • 糖尿病和代谢性疾病
  • 精神疾病
  • 心血管疾病
  • 呼吸系统疾病
  • 疼痛管理
  • 肥胖和文明病

9. 全球数位疗法市场（按最终用户划分）

  • 医院诊所
  • 雇主和企业的健康管理
  • 製药公司
  • 研究所
  • 其他的

第十章：全球数位疗法市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 併购
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十二章 企业概况

  • Pear Therapeutics
  • Teladoc Health
  • Propeller Health
  • Omada Health
  • Welldoc
  • Noom
  • Akili Interactive
  • Click Therapeutics
  • Biofourmis
  • Kaia Health
  • Livongo（Teladoc）
  • Mahana Therapeutics
  • Voluntis
  • Happify Health
  • Better Therapeutics
  • Big Health
  • BehaVR
Product Code: SMRC32837

According to Stratistics MRC, the Global Digital Therapeutics Market is accounted for $6.6 billion in 2025 and is expected to reach $29.5 billion by 2032 growing at a CAGR of 23.8% during the forecast period. Digital Therapeutics are evidence-based software applications designed to prevent, manage, or treat medical conditions through clinically validated digital interventions. Using behavioral science, cognitive therapies, real-time monitoring, and personalized treatment pathways, these platforms deliver measurable improvements in patient outcomes. They complement or substitute traditional therapies, especially in chronic disease management, mental health, metabolic disorders, and neurological conditions. Digital therapeutics operate under regulatory oversight and integrate with healthcare systems, ensuring data-driven care continuity and remote clinical support.

According to IQVIA's Digital Health Trends update, over 370 million unique patients now use prescription-grade digital therapeutics monthly, up from 110 million in 2020, signaling widespread clinical adoption for chronic disease management.

Market Dynamics:

Driver:

Growing adoption of remote patient management

Growing adoption of remote patient management is accelerating demand for digital therapeutics as healthcare ecosystems shift toward virtual care delivery. Rising prevalence of chronic conditions and increased comfort with telehealth platforms strengthen momentum. Digital tools enabling real-time monitoring, medication adherence tracking, and behavioral-health interventions offer measurable clinical benefits. As providers seek scalable, cost-efficient ways to manage large patient populations, digital therapeutics become essential in supporting continuous engagement, improving treatment adherence, and enhancing long-term health outcomes.

Restraint:

Limited reimbursement in many regions

Limited reimbursement in many regions continues to constrain large-scale adoption, particularly where regulatory pathways for software-based therapies remain underdeveloped. Payers often hesitate to classify digital therapeutics as reimbursable medical interventions, slowing integration into mainstream care. Fragmented evaluation standards and insufficient clinical-economic evidence further challenge funding decisions. As a result, providers and patients frequently bear out-of-pocket costs, impeding uptake. Until reimbursement frameworks mature globally, market penetration will remain uneven across different healthcare systems.

Opportunity:

Integration with personalized treatment pathways

Integration with personalized treatment pathways presents significant expansion potential as digital therapeutics increasingly leverage AI-driven insights, behavioral analytics, and patient-specific biomarkers. Tailored treatment programs improve efficacy, enhance engagement, and reduce relapse rates across chronic, metabolic, and mental-health disorders. Growing availability of real-world evidence strengthens clinical validation, encouraging adoption within evidence-based care models. As healthcare shifts toward precision medicine, digital platforms offering individualized therapy optimization gain prominence as key enablers of patient-centric interventions.

Threat:

Data-security breaches impacting patient trust

Data-security breaches impacting patient trust remain a critical threat as digital therapeutics rely heavily on sensitive behavioral, clinical, and biometric data. Cyber vulnerabilities in cloud infrastructure, mobile applications, and API integrations can lead to exposure of personal health information, eroding user confidence. Regulatory non-compliance may result in penalties and disrupt device approvals. Heightened public scrutiny around digital privacy could slow adoption unless platforms demonstrate robust cybersecurity frameworks and transparent data-handling practices.

Covid-19 Impact:

COVID-19 significantly accelerated digital therapeutics adoption as health systems prioritized remote care models during lockdowns. Patients increasingly adopted app-based interventions, digital cognitive-behavioral tools, and chronic-disease tracking platforms to avoid in-person visits. Clinical trials shifted to virtual formats, generating greater acceptance among regulators and providers. The pandemic heightened awareness of scalable digital care pathways, and post-pandemic demand remains strong as hybrid healthcare models persist, cementing digital therapeutics' long-term role in treatment delivery.

The chronic disease management systems segment is expected to be the largest during the forecast period

The chronic disease management systems segment is expected to account for the largest market share during the forecast period, resulting from rising prevalence of diabetes, cardiovascular disorders, respiratory diseases, and lifestyle-driven conditions. These platforms deliver structured monitoring, behavioral coaching, and therapy reinforcement, improving patient self-management. Providers increasingly rely on such systems to reduce hospitalizations, optimize care coordination, and enhance treatment adherence. Their proven clinical impact and broad applicability ensure sustained dominance in the digital therapeutics landscape.

The cloud-based platforms segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cloud-based platforms segment is predicted to witness the highest growth rate, propelled by their scalability, interoperability, and seamless data integration across healthcare systems. Cloud architectures enable real-time analytics, remote access, and continuous patient engagement at lower operational costs. They support multi-device synchronization, facilitating long-term monitoring and automated therapy adjustments. As demand rises for flexible, secure, and easily deployable digital-health solutions, cloud-based platforms rapidly emerge as the fastest-expanding segment.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, attributed to expanding digital-health initiatives, rapid smartphone penetration, and increasing burden of chronic diseases. Governments across China, India, Japan, and South Korea are accelerating adoption of remote-care programs and app-based therapeutic tools. Rising healthcare digitalization, favorable telemedicine regulations, and large patient populations further drive uptake. These conditions firmly position Asia Pacific as the leading market for digital therapeutics deployment.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR associated with strong reimbursement progress, rapid integration of digital therapeutics into clinical workflows, and robust venture-capital funding. The presence of leading digital-health innovators, supportive regulatory frameworks, and expanding partnerships between providers and technology firms accelerates adoption. Growing emphasis on outcome-based care and widespread acceptance of remote therapeutic interventions reinforce North America's status as the fastest-growing regional market.

Key players in the market

Some of the key players in Digital Therapeutics Market include Pear Therapeutics, Teladoc Health, Propeller Health, Omada Health, Welldoc, Noom, Akili Interactive, Click Therapeutics, Biofourmis, Kaia Health, Livongo (Teladoc), Mahana Therapeutics, Voluntis, Happify Health, Better Therapeutics, Big Health and BehaVR.

Key Developments:

In November 2025, Noom introduced Noom Med, combining digital therapeutics with telehealth prescribing for obesity and metabolic disorders, integrating behavioral science with AI-driven personalized coaching for sustainable health outcomes.

In October 2025, Noom introduced Noom Med, combining digital therapeutics with telehealth prescribing for obesity and metabolic disorders, integrating behavioral science with AI-driven personalized coaching for sustainable health outcomes.

In September 2025, Akili Interactive expanded its FDA-cleared digital therapeutic EndeavorRx, adding gamified modules for ADHD and cognitive disorders, while advancing clinical trials for broader neurological applications.

Treatment Types Covered:

  • Behavioral Health Programs
  • Chronic Disease Management Systems
  • Physical Rehabilitation Platforms
  • Lifestyle & Nutrition Interventions
  • Neurological Therapy Programs
  • Substance Use & Addiction Therapy

Deployments Covered:

  • Cloud-Based Platforms
  • On-Premise Platforms
  • Hybrid Digital Therapy Systems
  • Subscription-Based Platforms
  • Integrated Hospital Platforms

Technologies Covered:

  • AI-Based Therapy Platforms
  • Mobile & App-Based Solutions
  • Wearable-Integrated Systems
  • Remote Monitoring Technologies
  • VR/AR Therapy Platforms
  • Data Analytics & Cloud Systems

Applications Covered:

  • Diabetes & Metabolic Disorders
  • Mental Health Disorders
  • Cardiovascular Diseases
  • Respiratory Disorders
  • Pain Management
  • Obesity & Lifestyle Disorders

End Users Covered:

  • Hospitals & Clinics
  • Employers & Corporate Wellness
  • Pharmaceutical Companies
  • Research Organizations
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Digital Therapeutics Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Behavioral Health Programs
  • 5.3 Chronic Disease Management Systems
  • 5.4 Physical Rehabilitation Platforms
  • 5.5 Lifestyle & Nutrition Interventions
  • 5.6 Neurological Therapy Programs
  • 5.7 Substance Use & Addiction Therapy

6 Global Digital Therapeutics Market, By Deployment

  • 6.1 Introduction
  • 6.2 Cloud-Based Platforms
  • 6.3 On-Premise Platforms
  • 6.4 Hybrid Digital Therapy Systems
  • 6.5 Subscription-Based Platforms
  • 6.6 Integrated Hospital Platforms

7 Global Digital Therapeutics Market, By Technology

  • 7.1 Introduction
  • 7.2 AI-Based Therapy Platforms
  • 7.3 Mobile & App-Based Solutions
  • 7.4 Wearable-Integrated Systems
  • 7.5 Remote Monitoring Technologies
  • 7.6 VR/AR Therapy Platforms
  • 7.7 Data Analytics & Cloud Systems

8 Global Digital Therapeutics Market, By Application

  • 8.1 Introduction
  • 8.2 Diabetes & Metabolic Disorders
  • 8.3 Mental Health Disorders
  • 8.4 Cardiovascular Diseases
  • 8.5 Respiratory Disorders
  • 8.6 Pain Management
  • 8.7 Obesity & Lifestyle Disorders

9 Global Digital Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Employers & Corporate Wellness
  • 9.4 Pharmaceutical Companies
  • 9.5 Research Organizations
  • 9.6 Other End Users

10 Global Digital Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Pear Therapeutics
  • 12.2 Teladoc Health
  • 12.3 Propeller Health
  • 12.4 Omada Health
  • 12.5 Welldoc
  • 12.6 Noom
  • 12.7 Akili Interactive
  • 12.8 Click Therapeutics
  • 12.9 Biofourmis
  • 12.10 Kaia Health
  • 12.11 Livongo (Teladoc)
  • 12.12 Mahana Therapeutics
  • 12.13 Voluntis
  • 12.14 Happify Health
  • 12.15 Better Therapeutics
  • 12.16 Big Health
  • 12.17 BehaVR

List of Tables

  • Table 1 Global Digital Therapeutics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Digital Therapeutics Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 3 Global Digital Therapeutics Market Outlook, By Behavioral Health Programs (2024-2032) ($MN)
  • Table 4 Global Digital Therapeutics Market Outlook, By Chronic Disease Management Systems (2024-2032) ($MN)
  • Table 5 Global Digital Therapeutics Market Outlook, By Physical Rehabilitation Platforms (2024-2032) ($MN)
  • Table 6 Global Digital Therapeutics Market Outlook, By Lifestyle & Nutrition Interventions (2024-2032) ($MN)
  • Table 7 Global Digital Therapeutics Market Outlook, By Neurological Therapy Programs (2024-2032) ($MN)
  • Table 8 Global Digital Therapeutics Market Outlook, By Substance Use & Addiction Therapy (2024-2032) ($MN)
  • Table 9 Global Digital Therapeutics Market Outlook, By Deployment (2024-2032) ($MN)
  • Table 10 Global Digital Therapeutics Market Outlook, By Cloud-Based Platforms (2024-2032) ($MN)
  • Table 11 Global Digital Therapeutics Market Outlook, By On-Premise Platforms (2024-2032) ($MN)
  • Table 12 Global Digital Therapeutics Market Outlook, By Hybrid Digital Therapy Systems (2024-2032) ($MN)
  • Table 13 Global Digital Therapeutics Market Outlook, By Subscription-Based Platforms (2024-2032) ($MN)
  • Table 14 Global Digital Therapeutics Market Outlook, By Integrated Hospital Platforms (2024-2032) ($MN)
  • Table 15 Global Digital Therapeutics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 16 Global Digital Therapeutics Market Outlook, By AI-Based Therapy Platforms (2024-2032) ($MN)
  • Table 17 Global Digital Therapeutics Market Outlook, By Mobile & App-Based Solutions (2024-2032) ($MN)
  • Table 18 Global Digital Therapeutics Market Outlook, By Wearable-Integrated Systems (2024-2032) ($MN)
  • Table 19 Global Digital Therapeutics Market Outlook, By Remote Monitoring Technologies (2024-2032) ($MN)
  • Table 20 Global Digital Therapeutics Market Outlook, By VR/AR Therapy Platforms (2024-2032) ($MN)
  • Table 21 Global Digital Therapeutics Market Outlook, By Data Analytics & Cloud Systems (2024-2032) ($MN)
  • Table 22 Global Digital Therapeutics Market Outlook, By Application (2024-2032) ($MN)
  • Table 23 Global Digital Therapeutics Market Outlook, By Diabetes & Metabolic Disorders (2024-2032) ($MN)
  • Table 24 Global Digital Therapeutics Market Outlook, By Mental Health Disorders (2024-2032) ($MN)
  • Table 25 Global Digital Therapeutics Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 26 Global Digital Therapeutics Market Outlook, By Respiratory Disorders (2024-2032) ($MN)
  • Table 27 Global Digital Therapeutics Market Outlook, By Pain Management (2024-2032) ($MN)
  • Table 28 Global Digital Therapeutics Market Outlook, By Obesity & Lifestyle Disorders (2024-2032) ($MN)
  • Table 29 Global Digital Therapeutics Market Outlook, By End User (2024-2032) ($MN)
  • Table 30 Global Digital Therapeutics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 31 Global Digital Therapeutics Market Outlook, By Employers & Corporate Wellness (2024-2032) ($MN)
  • Table 32 Global Digital Therapeutics Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 33 Global Digital Therapeutics Market Outlook, By Research Organizations (2024-2032) ($MN)
  • Table 34 Global Digital Therapeutics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.